Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 7, 2024
Distillery Therapeutics
Inhibiting DNA-mediated inflammasome activation for recurrent atherosclerotic stroke
BioCentury | Jan 28, 2020
Emerging Company Profile
Quenching the flames of inflammatory cell death
With a $50M round, Quench is developing first-in-class gasdermin D inhibitors to treat inflammatory diseases.
BioCentury | Aug 16, 2019
Targets & Mechanisms
Biotechs explore the next generation of inflammasome targets, with caution
As interest in NLRP3 grows, biotechs are looking to the next crop of inflammasome targets
BioCentury | Apr 12, 2019
Product Development
NLRP3 early and often
The inflammasome space heats up as pharmas get in
BioCentury | Oct 26, 2018
Clinical News
Castle Creek discontinues Phase II of epidermolysis bullosa compound
BioCentury | Aug 30, 2018
Translation in Brief
Turning off the inflammasome
How inhibiting CMPK2 could block NLRP3-induced inflammasome activation
BioCentury | Jul 19, 2018
Translation in Brief
Inflammatory images
How inflammasome activation mediates contrast agent-induced acute kidney injury
Items per page:
1 - 10 of 31